Lighthouse Investment Partners LLC purchased a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,000 shares of the company's stock, valued at approximately $1,645,000.
Several other hedge funds also recently made changes to their positions in the company. SBI Securities Co. Ltd. purchased a new position in DaVita during the fourth quarter valued at $41,000. Coppell Advisory Solutions LLC raised its stake in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after buying an additional 100 shares during the last quarter. Canada Post Corp Registered Pension Plan purchased a new position in DaVita during the fourth quarter valued at $55,000. Venturi Wealth Management LLC raised its stake in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after buying an additional 152 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after buying an additional 131 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of research analysts have issued reports on DVA shares. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Barclays boosted their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. Finally, Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $166.33.
Read Our Latest Stock Analysis on DaVita
DaVita Stock Performance
DaVita stock traded up $1.63 during mid-day trading on Friday, reaching $145.23. 738,898 shares of the stock traded hands, compared to its average volume of 830,093. The stock has a market capitalization of $11.16 billion, a PE ratio of 13.52, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 12-month low of $131.44 and a 12-month high of $179.60. The business's 50-day moving average is $145.68 and its 200-day moving average is $153.39.
DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. The company had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. DaVita had a return on equity of 115.48% and a net margin of 7.31%. DaVita's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.26 earnings per share. As a group, sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.
DaVita Company Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
